Femara first aromatase inhibitor to indicate survival benefit versus tamoxifen when taken for five years after breast cancer surgery
Links shared publicly online about this topic.
- 2,413total visits
Femara first aromatase inhibitor to indicate survival benefit versus tamoxifen when taken for five years after breast cancer surgery
Basel, December 11, 2008 - New long-term data from a major international breast cancer study reports that postmenopausal woman with hormone receptor-positive early-stage breast cancer who took Femara (letrozole) for five years following surgery had a 13% (P=0.08) reduced risk of death, when compared with tamoxifen[1].
View full resource at novartis.com
Tags: Hormone, Cancer, Breast Cancer, Breast Cancer Medication, Women's Health, Femara, Surgery
Most Recently Shared on December 11, 2008 at 4:21 pm By:
Femara® first aromatase inhibitor to indicate survival benefit versus tamoxifen when taken for five years after .. http://twurl.nl/rodmqo
Advertisement
